WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H531340
CAS#: 144217-65-2
Description: YYA-021 novel potent HIV entry inhibitor.
Hodoodo Cat#: H531340
Name: YYA-021
CAS#: 144217-65-2
Chemical Formula: C18H27N3O2
Exact Mass: 317.21
Molecular Weight: 317.433
Elemental Analysis: C, 68.11; H, 8.57; N, 13.24; O, 10.08
Synonym: YYA-021; YYA 021; YYA021.
IUPAC/Chemical Name: N'-(4-Methylphenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
InChi Key: AYAGJQPDCPRMNG-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H27N3O2/c1-12-6-8-13(9-7-12)19-15(22)16(23)20-14-10-17(2,3)21-18(4,5)11-14/h6-9,14,21H,10-11H2,1-5H3,(H,19,22)(H,20,23)
SMILES Code: O=C(NC1CC(C)(C)NC(C)(C)C1)C(NC2=CC=C(C)C=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 317.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Mizuguchi T, Harada S, Miura T, Ohashi N, Narumi T, Mori H, Irahara Y, Yamada Y, Nomura W, Matsushita S, Yoshimura K, Tamamura H. A minimally cytotoxic CD4 mimic as an HIV entry inhibitor. Bioorg Med Chem Lett. 2016 Jan 15;26(2):397-400. doi: 10.1016/j.bmcl.2015.11.103. PubMed PMID: 26706175.
2: Hashimoto C, Narumi T, Otsuki H, Hirota Y, Arai H, Yoshimura K, Harada S, Ohashi N, Nomura W, Miura T, Igarashi T, Matsushita S, Tamamura H. A CD4 mimic as an HIV entry inhibitor: pharmacokinetics. Bioorg Med Chem. 2013 Dec 15;21(24):7884-9. doi: 10.1016/j.bmc.2013.10.005. PubMed PMID: 24189188.
3: Otsuki H, Hishiki T, Miura T, Hashimoto C, Narumi T, Tamamura H, Yoshimura K, Matsushita S, Igarashi T. Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic. J Gen Virol. 2013 Dec;94(Pt 12):2710-6. doi: 10.1099/vir.0.055590-0. PubMed PMID: 24026672.